We're Stopping Type 1 Diabetes, One Discovery at a Time | Diabetes UK

Take a look through some key milestones in early-stage type 1 diabetes and immunotherapies research, as teplizumab becomes the first one licensed in the UK. Thank you to those who support our work, this ground-breaking research wouldn't be possible without you. You can read more about this research here: https://www.diabetes.org.uk/our-research/about-our-research/our-impact/tackling-root-cause-type-1-diabetes